
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that the first patient has been dosed in Aclaris’ Phase 2a clinical trial of ATI-1777, an investigational topical “soft” Janus kinase …
Read More